Researchers found that patients with obesity had an average weight loss of 12.9% with semaglutide vs 5.6% with liraglutide ...

Severe obesity is already a significant problem for many children, especially since obese children often become obese adults.

Among patients receiving persistent medication at one year, 61% of patients prescribed semaglutide for obesity achieved at ...

In people with Type 2 diabetes, obesity, and chronic kidney disease, bariatric or weight loss surgery can significantly ...

Currently, there are no approved medications for treating nonmonogenic, nonsyndromic obesity in children under 12. While ...

The Clinical Trials Arena team investigates assets in infectious diseases, metabolic disorders, oncology and ophthalmology.

The study concentrates on the FDA-approved injectable medications semaglutide and liraglutide. A study conducted by the ...

Children who used the weight loss drug liraglutide in a late-stage trial lost significantly more weight than children who got ...

In people with Type 2 diabetes, obesity, and chronic kidney disease, bariatric or weight loss surgery can significantly protect kidney function ...

New study reveals semaglutide outperforms liraglutide in weight loss for obesity, highlighting key factors that contribute to significant weight reduction in patients. Study: One-Year Weight ...

Liraglutide has been found to safely reduce BMI in children aged 6 to under 12, offering a potential new treatment for pediatric obesity. The obesity medication liraglutide was found to be safe and ...

For patients with obesity receiving semaglutide or liraglutide, weight reduction at one year is associated with medication active agent.